Flagship Ventures Fund IV-Rx, L.P.'s Net Worth

$4.78 Billion

Estimate Recalculated Feb 23, 2024 04:08PM EST

Who is Flagship Ventures Fund IV-Rx, L.P.?

Flagship Ventures Fund IV-Rx, L.P. has an estimated net worth of $4.78 Billion. This is based on reported shares across multiple companies, which include Moderna, Inc., Seres Therapeutics, Inc., Editas Medicine, Inc., Rubius Therapeutics, Inc., Syros Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Axcella Health Inc., and Evelo Biosciences, Inc..

SEC CIK

Flagship Ventures Fund IV-Rx, L.P.'s CIK is 0001590973

Past Insider Trading and Trends

2018 was Flagship Ventures Fund IV-Rx, L.P.'s most active year for acquiring shares with 20 total transactions. Flagship Ventures Fund IV-Rx, L.P.'s most active month to acquire stocks was the month of April. 2016 was Flagship Ventures Fund IV-Rx, L.P.'s most active year for disposing of shares, totalling 47 transactions. Flagship Ventures Fund IV-Rx, L.P.'s most active month to dispose stocks was the month of April. 2022 saw Flagship Ventures Fund IV-Rx, L.P. paying a total of $52,069,996.75 for 33,716,630 shares, this is the most they've acquired in one year. In 2020 Flagship Ventures Fund IV-Rx, L.P. cashed out on 32,241,407 shares for a total of $68,219,276.30, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Moderna, Inc. (MRNA) Snapshot price: $100.17

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-36.29%
-11.05M
19.41M
Aug 17
Form 4
-1.71%
-1.00M
$68.22
-$68,219,276.30
57.31M
May 21 - May 22
Form 4
-29.46%
-12.28M
29.41M
May 11
Form 4
-5.75%
-9.67M
$18.87
-$8,196,935.61
158.57M
Dec 9 - Dec 11
Form 4
47.34M
47.34M
Dec 11
Form 3
0
0
No matching records found

Seres Therapeutics, Inc. (MCRB) Snapshot price: $1.035

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-39.84%
-7.91M
11.94M
Nov 23
Form 4
-12.02%
-2.00M
$27.60
-$27,600,000.00
14.64M
May 25
Form 4
11.63M
11.63M
Jun 25 - Jun 26
Form 3
0
0
No matching records found

Editas Medicine, Inc. (EDIT) Snapshot price: $7.155

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-30.97%
-1.55M
3.46M
Aug 11
Form 4
4.96M
4.96M
Feb 8
Form 3
0
0
No matching records found

Rubius Therapeutics, Inc. (RUBY) Snapshot price: $0.057

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+185.29%
33.3M
51.27M
Jul 20
Form 3
0
0
No matching records found

Syros Pharmaceuticals, Inc. (SYRS) Snapshot price: $7.14

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-35.64%
-1.66M
2.99M
Aug 17
Form 4
+47.55%
4.59M
$12.50
$5,000,000.00
14.25M
Jul 6
Form 3
0
0
No matching records found